<DOC>
	<DOCNO>NCT00003616</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness irinotecan treating patient progressive recurrent malignant glioma .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Progressive Recurrent Malignant Glioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity irinotecan patient progressive recurrent malignant glioma . II . Define safety profile every 3 week dose irinotecan patient . III . Characterize pharmacokinetic profile regimen patient . IV . Assess evidence antitumor activity patient . V. Determine efficacy irinotecan patient measure 6 month progression-free survival objective tumor response . VI . Evaluate safety profile irinotecan patient phase II study . OUTLINE : This dose escalation study . Patients stratify accord concurrent enzyme-inducing antiepileptic drug ( EIAEDs ) ( yes v ) . Group A ( without EIAEDs ) : Patients receive irinotecan IV 90 minute day 1 , follow 3 week rest . Group B ( EIAEDs ) : Patients receive treatment dose escalation perform cohort 3 patient . The maximum tolerated dose ( MTD ) define dose 2 6 patient experience dose limit toxicity . The Phase I MTD start dose recommend use Phase II portion study . Treatment continue every 3 week 12 month absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year , every 3 month 1 year , every 4 month 1 year , every 6 month disease progression . Patients follow every 4 month survival . PROJECTED ACCRUAL : Up 30 patient accrued phase I within 10 month . A total 48 patient accrue phase II within 6-8 month .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive recurrent primary malignant glioma Phase I ( exclude group A patient ) : No 2 prior chemotherapy regimen , include 1 prior adjuvant therapy 1 prior regimen recurrent progressive tumor , 2 prior regimen progressive tumor Phase II and/or group A patient : No 1 prior chemotherapy regimen , either adjuvant recurrent disease Measurable disease MRI CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 3 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No uncontrolled hypertension No unstable angina No symptomatic congestive heart failure No myocardial infarction within 6 month No serious uncontrolled cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No severe nonmalignant systemic disease active infection No concurrent alcoholism drug abuse No psychosis HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy No concurrent sargramostim ( GMCSF ) Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , suramin ) No prior irinotecan , topotecan , topotecan 1 inhibitor No concurrent chemotherapy Endocrine therapy : Stable decrease dosage corticosteroid within 72 hour study entry ( phase II ) No concurrent immunosuppressive agent No concurrent hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy Patients prior interstitial brachytherapy stereotactic radiosurgery must confirmation progressive disease No concurrent radiotherapy Surgery : At least 3 week since prior resection Other : Acute toxic effect ( exclude neurotoxicity alopecia ) prior therapy must resolve No concurrent valproic acid single agent Concurrent enzymeinducing antiepileptic drug ( EIAED ) without steroid allow No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
</DOC>